ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

risvutatug rezetecan

Also written as “HS-20093”, “HS-20093 for Injection” and “Risvutatug rezetecan (Ris-Rez)”.

In GlaxoSmithKline’s pipeline, ADC targeting B7-H3. Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Osteosarcoma · Neoplasms · Prostatic Neoplasms, led by 3 companies.

Drug pageRisvutatug rezetecan: every studyAll 32 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 6, 202430 company-led studies, 26 open or runningLicense: Hansoh → GSK, Dec 2023Next primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group2117 open or runningphase 3since Jul 6, 2024Feb 18, 2022Dec 30, 2026phase 1 · NCT06699576
GlaxoSmithKlineits history only88 open or runningphase 3since Jul 30, 2025Mar 3, 2022Nov 5, 2027phase 3 · NCT07099898
Jiangsu HengRui Medicineits history only11 open or runningphase 2since Nov 13, 2025Nov 13, 2025Dec 2028phase 2 · NCT07230106
  • Named in GlaxoSmithKline’s own pipeline as risvutatug rezetecan GSK5764227, phase 3, as of Sep 30, 2026 (source).
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-20093 (B7-H3 ADC), phase 3, as of Aug 26, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseGSK licensed it from Hansoh, for everywhere outside mainland China, Hong Kong, Macau and Taiwan.Announced Dec 20, 2023 · Source: GSK, Dec 20, 2023

How Jiangsu HengRui Medicine relates to it is not in the registry or these sources.

History and studies of Hansoh Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Feb 18, 2022.

  1. Dec 20, 2023GSK licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong, Macau and Taiwan · announced · GSK
  2. Mar 18, 2024Phase 1 study in Advanced Solid TumorNCT06332170 · 610 planned · China
  3. Jul 6, 20242 phase 3 studies in Small Cell Lung CarcinomaNCT06498479, NCT06526624
  4. Nov 19, 2024Phase 1 study in OsteosarcomaNCT06699576 · 448 planned
  5. Feb 9, 2025Phase 1 study in Colorectal NeoplasmsNCT06825624 · 560 planned · China
  6. Apr 17, 2025Phase 3 study in OsteosarcomaNCT06935409 · 122 enrolled · China
  7. Jul 3, 2025Phase 1 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)NCT07063407 · 50 planned
  8. Jul 10, 2025Named risvutatug rezetecanINNProposed as its International Nonproprietary Name in WHO's List 133 · before, HS-20093, GSK5764227
  9. Aug 4, 2025Phase 1 study in Advanced Prostate CancerNCT07115446 · 63 planned · China
  10. Sep 9, 2025Phase 1 study in Advanced Solid TumorsNCT07186452 · 18 planned · China
  11. Jan 15, 2026Phase 1 study in Advanced Gastric and Gastroesophageal Junction AdenocarcinomaNCT07462923 · 40 enrolled · China
  12. Mar 6, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07464327 · 450 planned
  13. May 26, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaNCT07621601 · 494 planned
  14. Aug 13, 2026Phase 1 study in Small Cell Lung CarcinomaNCT07892625 · 338 planned
  15. Aug 13, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07824882 · 76 planned · China
  16. Oct 20, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07899086 · 102 planned

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in OsteosarcomaNCT06699576
  2. Dec 31, 2026Primary completion: phase 1 study in Advanced Gastric and Gastroesophageal Junction AdenocarcinomaNCT07462923
  3. Nov 30, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT06526624
  4. Dec 2027Primary completion: phase 1 study in Advanced Prostate CancerNCT07115446

TargetBeta

“ADC targeting B7-H3”the company's pipeline, read by Claude · source
“B7-H3 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of risvutatug, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the T-cell checkpoint ligand B7-homologue 3 (B7-H3, CD276) covalently ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
ifinatamab deruxtecanMerckphase 316
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 313
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 35
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

All 21 Hansoh Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07899086Carcinoma, Non-Small-Cell Lung1Not yet recruitingDec 31, 2027102
NCT07892625Small Cell Lung Carcinoma1Not yet recruitingSep 15, 2028338
NCT07824882Carcinoma, Non-Small-Cell Lung · China2RecruitingMar 30, 202876
NCT07621601Esophageal Squamous Cell Carcinoma3Not yet recruitingDec 31, 2030494
NCT07464327Carcinoma, Non-Small-Cell Lung3Not yet recruitingDec 31, 2028450
NCT07462923Advanced Gastric and Gastroesophageal Junction Adenocarcinoma · China1Active, not recruitingDec 31, 202640
NCT07186452Advanced Solid Tumors · China1RecruitingJul 31, 202618
NCT07115446Advanced Prostate Cancer · China1RecruitingDec 202763
NCT07063407Extensive Stage Small Cell Lung Cancer (ES-SCLC)1Not yet recruitingApr 30, 202650
NCT06935409Osteosarcoma · China3CompletedJun 17, 2026122
NCT06825624Colorectal Neoplasms · China1RecruitingOct 31, 2026560
NCT06699576Osteosarcoma1Not yet recruitingDec 30, 2026448
NCT06526624Small Cell Lung Carcinoma3Not yet recruitingNov 30, 2027406
NCT06498479Small Cell Lung Carcinoma · China3CompletedAug 20, 2026461
NCT06332170Advanced Solid Tumor · China1RecruitingMay 30, 2026610
NCT06112704Esophageal Neoplasms · China2RecruitingJul 31, 2026220
NCT06052423Extensive Stage Small Cell Lung Cancer (ES-SCLC)2WithdrawnJun 30, 20250
NCT06007729Squamous Cell Carcinoma of Head and Neck · China2RecruitingDec 12, 2025170
NCT06001255Metastasis Castration Resistant Prostate Cancer(mCRPC) · China2RecruitingDec 31, 2024120
NCT05830123Osteosarcoma · China2RecruitingDec 31, 2025170
NCT05276609Advanced Solid Tumor · China1UNKNOWNDec 31, 2023177

How it is read

Names in the registry

  • “HS-20093”, 15 entries
  • “HS-20093 for Injection”, 4 entries
  • “Risvutatug rezetecan (Ris-Rez)”, 2 entries
  • “GSK5764227”, 2 entries
  • “Ris-Rez”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.